Compare Manchester United PLC (MANU) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manchester United PLC vs Merck & Co., Inc. — how do they compare? Manchester United PLC trades at $22.44 (market cap $3.80B), while Merck & Co., Inc. trades at $125.53 (market cap $307.25B). The key difference: Merck & Co., Inc. is far larger — about 80.9× Manchester United PLC's market cap, and Merck & Co., Inc. pays the higher dividend (2.73%). Which is the better fit depends on your goals.
| MANU | MRK | |
|---|---|---|
Market Cap | $3.80B | $307.25B |
Sector | Media | Health |
52-Week High | $23.53 | $129.52 |
52-Week Low | $15.10 | $77.60 |
Enterprise Value | $4.72B | $350.66B |
Dividend Yield | 1.26% | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Manchester United (MANU) trades at $22.05, down 0.81% today, with a bullish technical signal from moving averages but mixed recent earnings performance. Revenue grew to $667M in 2025, yet net losses persist at -$33M. The company is advancing a new 100,000-seat stadium project, a key long-term growth driver, while securing Champions League qualification boosts future revenue prospects.
Outlook hinges on stadium development execution and sustained sporting success to drive profitability. Risks include high debt levels and inconsistent earnings. Analysts are cautiously optimistic with 40% buy ratings, but investors should monitor cash flow trends amid significant capital expenditures.
MRK trades at $125.85, down 1.29% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $137.30 suggesting 9% upside. Recent earnings have consistently beaten expectations, with Q1 2026 loss narrower than forecast. The company maintains strong profitability with a 73.91% gross margin and 18.97% ROE, while actively expanding its pipeline through acquisitions like Terns Pharmaceuticals.
Outlook remains positive driven by earnings beats and strategic M&A, but risks include rising debt levels and patent expirations. The stock offers a dividend yield with upcoming payment, supported by institutional accumulation. Valuation multiples are elevated, requiring sustained growth to justify current levels amid competitive and regulatory pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Manchester United PLC
Manchester United PLC operates a professional football club together with related and ancillary activities. The company manages the soccer team and all affiliated club activities of the Manchester United Football Club, which includes the media network, foundation, fan zone, news, sports features, and team merchandise. Manchester United is based in England. The company has three principal sectors from which most of the revenue is generated, including Commercial, Broadcasting, and Matchday.
Read more on MANU →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
